305 related articles for article (PubMed ID: 15590971)
1. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
2. Direct interference of HIV protease inhibitors with pancreatic beta-cell function.
Düfer M; Neye Y; Krippeit-Drews P; Drews G
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jun; 369(6):583-90. PubMed ID: 15197535
[TBL] [Abstract][Full Text] [Related]
3. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
4. HIV protease inhibitors acutely impair glucose-stimulated insulin release.
Koster JC; Remedi MS; Qiu H; Nichols CG; Hruz PW
Diabetes; 2003 Jul; 52(7):1695-1700. PubMed ID: 12829635
[TBL] [Abstract][Full Text] [Related]
5. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic dose of HIV-1 protease inhibitor saquinavir does not permanently influence early insulin signaling.
Algenstaedt P; Daneshi S; Schwarzloh B; Hennigs N; Hamann A; Hansen-Algenstaedt N; Beisiegel U
Exp Clin Endocrinol Diabetes; 2003 Dec; 111(8):491-8. PubMed ID: 14714271
[TBL] [Abstract][Full Text] [Related]
7. [Impairment of IRS-2 signaling in rat insulinoma INS-1 cells by nelfinavir].
Zhou JQ; Xiang Z; Schutt M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2004 Jul; 33(4):311-4. PubMed ID: 15269981
[TBL] [Abstract][Full Text] [Related]
8. The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling.
Cammalleri C; Germinario RJ
J Lipid Res; 2003 Jan; 44(1):103-8. PubMed ID: 12518028
[TBL] [Abstract][Full Text] [Related]
9. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
[TBL] [Abstract][Full Text] [Related]
11. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors.
Ben-Romano R; Rudich A; Török D; Vanounou S; Riesenberg K; Schlaeffer F; Klip A; Bashan N
AIDS; 2003 Jan; 17(1):23-32. PubMed ID: 12478066
[TBL] [Abstract][Full Text] [Related]
12. [Effects of various HIV protease inhibitors on function of rat insulinoma cells].
Zhou JQ; Li WP; Xiang Z; Schutt M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2006 May; 35(3):251-4. PubMed ID: 16764025
[TBL] [Abstract][Full Text] [Related]
13. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
14. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
15. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Lenhard JM; Furfine ES; Jain RG; Ittoop O; Orband-Miller LA; Blanchard SG; Paulik MA; Weiel JE
Antiviral Res; 2000 Aug; 47(2):121-9. PubMed ID: 10996400
[TBL] [Abstract][Full Text] [Related]
16. [Resistance to protease inhibitors].
Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
[No Abstract] [Full Text] [Related]
17. Resistance to human immunodeficiency virus type 1 protease inhibitors.
Boden D; Markowitz M
Antimicrob Agents Chemother; 1998 Nov; 42(11):2775-83. PubMed ID: 9797203
[No Abstract] [Full Text] [Related]
18. HIV protease inhibitors: suppression of insulin secretion by inhibition of voltage-dependent K+ currents and anion currents.
Neye Y; Düfer M; Drews G; Krippeit-Drews P
J Pharmacol Exp Ther; 2006 Jan; 316(1):106-12. PubMed ID: 16162820
[TBL] [Abstract][Full Text] [Related]
19. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.
Dailly E; Thomas L; Kergueris MF; Jolliet P; Bourin M
J Chromatogr B Biomed Sci Appl; 2001 Jul; 758(2):129-35. PubMed ID: 11486821
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
